PTGX241220C5000
- 0.00
- 0.000.00%
Protagonist Therapeutics Newsroom
Express News | Protagonist Therapeutics Inc : Btig Raises Target Price to $67 From $51
Express News | Protagonist Selects PN-881 As Development Candidate For Treatment Of Immune-Mediated Skin Disease
ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. "Rusty" Williams, M.D., Ph.D. as Chairman of the Board
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $50 to $65
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
TD Cowen Remains a Buy on Protagonist Therapeutics (PTGX)
Protagonist Therapeutics: Promising Growth With ICONIC Phase 3 Success and Strategic Partnerships
Express News | Protagonist Therapeutics Inc Shares Down 5.9% at $38 in Relatively Light Trading Volume After the Bell Following Update From Phase 3 Study of Plague Psoriasis Treatment
Express News | Protagonist Therapeutics-Iconic-Lead Achieved Its Co-Primary Endpoints of Pasi-90 and Iga of 0 or 1 at Week 16
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
10 Health Care Stocks With Whale Alerts In Today's Session
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $60
Protagonist Therapeutics Analyst Ratings
BTIG Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $51
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $50
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $51
Protagonist Therapeutics (PTGX) Gets a Buy From J.P. Morgan
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Protagonist Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Protagonist Therapeutics Inc : JP Morgan Raises Target Price to $51 From $48